IN PARTNERSHIP WITH THE GLOBAL GOOD
ACCESS BIO AND GLOBAL GOOD RELEASE ULTRA-SENSITIVE P. FALCIPARUM MALARIA DETECTION KIT THAT DISPLAYS UP TO FIVE-FOLD IM
New rapid diagnostic test now available to research organizations for low parasitemia settings
December 18, 2019AccessBio (KOSDAQ: 950130) and collaboration partner Global Good have developed a new ultra-sensitive rapid diagnostic test (uRDT) that is five times more analytically sensitive in identifying histidine-rich protein 2 (HRP2) antigens than currently available uRDTs.
“With decades of experience optimizing lateral flow assays, we have carefully designed the system together with Global Good to increase sensitivity without significantly increasing the complexity or cost of the assay,” said Young Ho Choi, Founder and CEO of AccessBio. “And now the assay is available for use by malaria elimination research organizations and antenatal screening clinics where low parasitemia counts complicate detection.”
“Our team confirmed a reproduceable and consistent five-fold improvement in detection limits with more than 95% specificity through trials conducted at the IV Laboratory,” said Kevin Nichols, Principal Investigator for Flow-based Diagnostics at the Intellectual Ventures Laboratory.
“AccessBio has now incorporated this capability into a new uRDT research product that could complement P. falciparum elimination efforts where a downward trend of falciparum cases has been observed. Tests that can detect very low levels of malaria intensity at the point of care are essential to reach the malaria elimination milestones of the WHO Global Technical Strategy for Malaria 2016-2030,” said Nichols.
“As highlighted in the recently released 2019 World Malaria Report, pregnant women and children continue to be the most vulnerable populations to malaria. And with most pregnant mothers typically attending at least one routine pre-birth visit to a clinic, antenatal settings may also present an opportune moment for future uRDT research trials to screen for malaria,” said Nichols.
Read more about AccessBio and Global Good’s collaborative work on HRP2-deleted detection kits here.